Slan Medicinal Holdings and group companies are part of a network of independent associated companies focused on improving patient health and addressing unmet medical needs by acquiring, developing, manufacturing and commercializing specialty pharmaceutical products in niche orphan disease and specialty market segments.
Mr. Burke serves as the controlling shareholder and/or Chairman of the Board of Eolas Pharma Teoranta, West Therapeutic Development, LLC, Buckeye Pharmaceuticals, LLC and Orphan Pharmacy Services, LLC.
Prior to founding MMB Healthcare Investments, Mr. Burke was one of three founding investors and an operating executive at Marathon Pharmaceuticals, LLC, a specialty pharmaceutical company that acquired, developed, grew and then divested specialty and orphan disease pharmaceutical products.
Prior to Marathon, Mr. Burke was one of the first members of the Ovation Pharmaceuticals’ executive team. As an operating executive he focused on sales, marketing, business development and the assessment of acquisition targets. In 2008, he was named one of the “45 under 45 Emerging Pharma Leaders” by Pharmaceutical Executive. He became chief commercial officer of Lundbeck Inc. following Lundbeck’s acquisition of Ovation in 2009.
Prior to Ovation, Mr. Burke spent eight years in the Pharmaceuticals Products Division at Abbott Laboratories, where he served in various sales and marketing roles and managed specialty market and primary care product lines.
Mr. Burke holds a B.A. from Providence College and an M.B.A. from the Kellogg School of Management at Northwestern University.
Mr. Burke serves as an Executive Board Member of the MMB Healthcare network of independent associated healthcare companies. In this role he provides insight and counsel on mergers and acquisitions as well as directing corporate financing strategy for the various companies.
Mr. Burke is an accomplished finance executive with over 25 years of experience in the real estate, principal investment, private equity, fixed income and investment banking sectors, primarily with Lehman Brothers, Dresdner Kleinwort and Wachovia Securities International, with the last 16 years in London and the prior 10 years in New York.
Mr. Burke has successfully operated in both principal and advisory roles in multiple international jurisdictions. He has completed equity and debt transactions in the real estate; mortgage; infrastructure; sports and media; asset backed operating company sectors raising, financing or investing more than $15 billion in over 50 transactions.
Mr. Burke received a B.A. from Georgetown University in 1988 and an MBA in finance from Columbia University in 1993.
Mr. Burke is based in London.
Dr. Collins serves as the Chief Development Officer for the MMB Healthcare companies.
As a career R&D leader, Dr. Collins has led or had senior leadership positions in multiple pharmaceutical and biotech companies in a wide range of therapeutic areas, resulting in over a dozen approved drugs. In addition to leading R&D efforts for the MMB enterprise, he is also serving as Chairman of Xalud Therapeutics, a biologics based anti-inflammatory focused company in phase 2 clinical studies with initial uses in treatment of osteoarthritis and pain. Most recently he was President and CEO of Biscayne Neurotherapeutics, a small molecule clinical stage company with focus on CNS applications which was sold to Supernus Pharmaceuticals in October of 2018.
Prior to that he was the CEO, President of NeuroTherapeutics Pharma, an early stage biotechnology company where he raised $42 million to advance novel therapeutics for CNS. He served on the board of Spinifex Pharmaceuticals which was acquired by Novartis for $725 million on 2016.
Prior to NeuroTherapeutics, he was Chief Scientific Officer & VP for Clinical Affairs of Ovation Pharmaceuticals, an oncology and CNS-focused biopharmaceutical company acquired by Lundbeck A/S for $963 million.
Prior to Ovation, Dr. Collins served as a Global Director at Johnson & Johnson, overseeing early-stage development of a variety of agents and as a member of the global in-licensing advisory team.
Prior to Johnson and Johnson, he worked in Abbott Laboratories’ Pharmaceutical and Hospital Products Divisions where he developed drugs for multiple indications and was responsible for all preclinical and clinical programs supporting the successful approval of multiple NDA and sNDA submissions. Prior to industry, Dr. Collins served on the faculty of medicine at Case Western Reserve University and the University of California-San Francisco.
He earned his MD and PhD at Case Western Reserve University after completing undergraduate studies in Physics at the University of California, Berkeley. Dr. Collins currently serves on the Boards of a number of small molecule and biologics biotech companies.
Mr. Reinfelds serves as the General Counsel & VP, Legal Affairs of the MMB Healthcare network of independent associated healthcare companies. In this role he manages mergers and acquisitions and corporate legal matters. Mr. Reinfelds executed the group’s first acquisition, Cosyntropin Depot, with follow-on acquisitions and transactions providing the basis for the formation of the EMEA companies.
Prior to his role with the MMB Healthcare network of independent associated healthcare companies, Mr. Reinfelds was counsel for Marathon Pharmaceuticals, LLC from 2014 to 2017. Prior to his role at Marathon, he was with Lundbeck LLC prior to 2014 and with Ovation Pharmaceuticals, Inc. from 2008 until its acquisition by Lundbeck in 2009.
Mr. Reinfelds earned his J.D. from The John Marshall Law School and his Ph.D in Biology from Illinois Institute of Technology. He is a member of the Illinois bar and is licensed to practice before the United States Patent and Trademark Office as a registered patent attorney.